In May, 2015, the U.S. Food and Drug Administration (FDA) announced that it would conduct a safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as Invokana, used to treat type 2 diabetes. The Agency announced the results of the review on December 4. SGLT2 inhibitors will now carry new warnings about the risks of ketoacidosis … [Read more...]
FDA Warns of Invokana Bone Fracture Risk
On September 10, 2015, the U.S. Food and Drug Administration (FDA) announced that it is strengthening the warning on Invokana (canagliflozin) and Invokamet to reflect the risk of bone fracture and decreased bone mineral density associated with using the drugs. Invokana is used to treat Type 2 diabetes. It is in a class of drugs called … [Read more...]
Experts Advised against Invokana FDA Approval
In March, 2013, the U.S. Food and Drug Administration (FDA) approved Invokana (canagliflozin) for use in treating type 2 diabetes in spite of the fact that five out of 15 experts voted against approving the drug and those who voted in favor of the drug had some serious reservations about its safety. The FDA questioned the safety of Invokana too, … [Read more...]
Symptoms of Invokana Kidney Failure
If you or someone you care about is taking Invokana (canagliflozin) for type 2 diabetes, you need to know how to recognize the signs of kidney failure. Kidney failure is fatal if left untreated. Those who are treated early enough may avoid permanent injury. Invokana was linked to at least 54 cases of renal impairment and kidney failure in its first … [Read more...]
Invokana Injuries and Side Effects
Invokana (canagliflozin) was the first in a new class of drugs used to treat type 2 diabetes, called sodium-glucose cotransporter-2 (SGLT2) inhibitors, to receive approval by the U.S. Food and Drug Administration. (FDA). It was approved in March, 2013, and within a year of hitting the market the drug had been linked to at least 457 serious adverse … [Read more...]
Recent Comments